• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?

0
  • by alexperjescuadmin
  • in Cardiovascular
  • — 25 Mar, 2007
Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?
AudioMedica News
Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?
Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?
00:00 /
RSS Feed
Share
Link
Embed
David Moliterno

DAVID MOLITERNO, University of Kentucky, Lexington

REFERENCE: American College of Cardiolgy New Orleans, March 24th Late Breaking Trials
An oral thrombin receptor antagonist, SCH 530348 has proved safe and effective, and may be better than conventional anti-coagulation treatments for patients receiving percutaneous coronary intervention. Results of the TRA-PCI study were presented at the ACC’s New Orleans meeting by David Moliterno who discussed the new data with Peter Goodwin.

[audio:https://www.audiomedica.com/podcasting/cardio/acc2007/070325_david_moliterno.mp3]
Share

Tags: accanti-coagulationcardiovascularcoronaryreceptorthrombin

You may also like...

  • Audio Journal of Cardiovascular Medicine 11.3, October 2005 Audio Journal of Cardiovascular Medicine 11.3, October 2005 9 Jan, 2006
  • Deepak Bhatt SAVOR-TIMI 53 study: saxagliptin had better glucose control than placebo but no cardiovascular benefit 22 Sep, 2013
  • Bivalirudin For Angioplasty: Expensive Heparin? Bivalirudin For Angioplasty: Expensive Heparin? 30 Apr, 2008
  • Cardiac Re-Synchronisation Cuts Sudden Death Cardiac Re-Synchronisation Cuts Sudden Death 12 Sep, 2005

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story When Good Cells Go Bad: The Stem Cell Origin of Cancers
  • Next story Rapid Genotype Assay for Individualized Warfarin Dosing
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • Ribociclib Aids First-Line Endocrine Therapy in…
    • Head and Neck Cancer Therapy De-Escalation: A…
    • ALK—Targeted Lung Cancer Drugs Benefited Real…
  • Home
  • Cardiovascular
  • Thrombin Receptor Antagonist: Advantages in Percutaneous Coronary Intervention?

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.